Literature DB >> 7811249

Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene.

D L Winslow1, E D Anton, R A Horlick, R J Zagursky, R J Tritch, H Scarnati, K Ackerman, L T Bacheler.   

Abstract

A DNA clone of HIV-1 containing the full-length infectious viral sequence was cleaved at a unique Nco I restriction site within the viral genome, and DNA fragments containing the 5' and 3' portions of the HIV genome were subcloned into separate plasmid vectors. The 5' 'half-virus' construct was further modified by incorporating a class IIS restriction site, Esp3I, near the 3' end of the protease gene of HIV. This site, in combination with a natural ApaI site near the 5' end of the protease gene, creates a convenient cassette shuttle vector in which the protease coding region can be easily replaced. Recombinant viruses containing protease genes either altered by site-directed mutagenesis or amplified from clinical or laboratory isolates can be reconstructed. The DNA fragment containing the protease gene is first subcloned into the 5' half-virus shuttle vector plasmid. Infectious recombinant virus is subsequently recovered by cotransfecting 5' and 3' half-virus plasmids linearized at their common Nco I sites into mammalian cells. This method was successfully applied to constructing viruses containing various substitutions in protease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811249     DOI: 10.1006/bbrc.1994.2857

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.

Authors:  J Martinez-Picado; L Sutton; M P De Pasquale; A V Savara; R T D'Aquila
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Authors:  L Bacheler; S Jeffrey; G Hanna; R D'Aquila; L Wallace; K Logue; B Cordova; K Hertogs; B Larder; R Buckery; D Baker; K Gallagher; H Scarnati; R Tritch; C Rizzo
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

Authors:  A Carrillo; K D Stewart; H L Sham; D W Norbeck; W E Kohlbrenner; J M Leonard; D J Kempf; A Molla
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.